Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Protalix Receives Complete Response Letter Regarding BLA


RTTNews | Apr 28, 2021 02:08AM EDT

02:08 Wednesday, April 28, 2021 (RTTNews.com) - Protalix BioTherapeutics, Inc. (PLX), and Chiesi Global Rare Diseases said they received a Complete Response Letter from the FDA regarding the Biologics License Application seeking accelerated approval of pegunigalsidase alfa (PRX102) for the proposed treatment of adult patients with Fabry disease. The BLA submission for PRX102 included a comprehensive set of preclinical, clinical, and manufacturing data compiled from the completed phase I/II clinical trial of PRX102.

"While disappointing, we remain confident in the strength of our data and in the depth of our program," said Dror Bashan, Protalix's President and Chief Executive Officer.

Read the original article on RTTNews ( https://www.rttnews.com/3188776/protalix-receives-complete-response-letter-regarding-bla-for-prx-102-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC